lutetium Lu 177 dotatate

Also Known As:

(177Lu-DOTAOTyr3)octreotate; (177lutetium-DOTA(O)Tyr3)octreotate; 177Lu-DOTATATE; DOTATATE-177Lu; Lu-177 DOTATE; Lutathera; lutetium (177Lu) oxodotreotide; lutetium oxodotreotide Lu-177

Networked: 247 relevant articles (27 outcomes, 40 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organometallic Compounds: 64
  - lutetium Lu 177 dotatate: 247
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - lutetium Lu 177 dotatate: 247
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - lutetium Lu 177 dotatate: 247

Experts

1.	Basu, Sandip: 23 articles (09/2022 - 12/2014)
2.	Sundin, Anders: 10 articles (04/2021 - 02/2015)
3.	Ahmadzadehfar, Hojjat: 9 articles (08/2021 - 01/2018)
4.	Sandström, Mattias: 9 articles (02/2021 - 02/2015)
5.	de Herder, Wouter W: 8 articles (07/2022 - 01/2018)
6.	Parghane, Rahul V: 8 articles (11/2021 - 06/2017)
7.	Makis, William: 8 articles (02/2016 - 02/2015)
8.	McCann, Karey: 8 articles (02/2016 - 02/2015)
9.	McEwan, Alexander J B: 8 articles (02/2016 - 02/2015)
10.	Assadi, Majid: 7 articles (08/2021 - 10/2019)

Related Diseases

1.	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/01/2021 - "Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors." 12/07/2022 - "177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials." 07/01/2022 - "Neuroendocrine tumor patients treated with 177Lu-DOTATATE between 2000 and 2015 in our phase II trial with available laboratory data were included. " 01/01/2022 - "Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study." 01/01/2021 - "To study changes in pituitary function in patients with neuroendocrine tumors (NETs) treated with dosimetry-based 177Lu-DOTATATE to detect possible late toxicity. "
2.	Neoplasms (Cancer) 01/01/2017 - "Conclusion:177Lu-OPS201 exhibits higher tumor uptake, longer tumor residence time, and improved tumor-to-kidney dose ratio compared with 177Lu-DOTATATE and 90Y-OPS201. " 12/01/2021 - "A cancer-specific instrument, EORTC QLQ-C30, was used to collect the data for 177Lu-DOTATATE within clinical studies, but utility-based instruments were not included. " 05/11/2020 - "This study indicates that for 177Lu-DOTATATE PRRT, accurate estimates of absorbed dose for organs and tumors may be estimated from scans at 24 h, 72 h, and 1 week post-treatment without an earlier scan. " 02/05/2020 - "The primary endpoint of this study is the difference in tumor-to-non-tumor ratio of 177Lu-DOTATATE uptake between the two liver lobes on post-treatment SPECT/CT (IA versus IV). " 01/01/2019 - "This study aimed to quantify the impact of AA co-infusion on the pharmacokinetics of 177Lu-Dotatate in cancer patients and to evaluate its relationship with toxicity during the first treatment cycle (C1). "
3.	Meningioma (Meningiomas) 01/01/2022 - "The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 177Lu-DOTATATE and an overall analysis of progression-free survival at 6 months (PFS-6) of the same relevant studies in the literature. " 12/01/2023 - "Adult patients with progressive intracranial meningiomas received 177Lu-DOTATATE at a dose of 7.4 GBq (200 mCi) every eight weeks for four cycles. " 01/01/2022 - "Eight patients with recurrent and progressive WHO grade II meningiomas were treated after multimodal pretreatment with 177Lu-DOTATATE between 2019 and 2022. " 09/01/2020 - " Seven patients with progressive intracranial meningioma (median age 73 years, interquartile range 60-76; 5 WHO II, 2 WHO I; 5 multifocal) received a median of 4 cycles 2 3 4 of PRRT with 177Lu-DOTATATE in eight-week intervals. " 09/01/2020 - "We present our experience on PPRT with 177Lu-DOTATATE in progressive meningioma with a special emphasis on state-of-the-art response assessment. "
4.	Neoplasm Metastasis (Metastasis) 10/01/2021 - "IA administration of 177Lu-DOTATATE results in higher concentration and absorbed dose in hepatic metastases in patients of GEPNETs as compared to a single dose of PRRT administered through standard IV route, and thus seems to be a powerful tool to improve the efficacy of PRRT. " 10/01/2019 - "This study aimed to compare different image-based methods for bone marrow dosimetry and study the dose-response relationship during treatment with 177Lu-DOTATATE in patients with and without skeletal metastases. " 06/15/2018 - "In this phase 2 study 30-48 patients with > 3 measurable liver metastases according to RECIST 1.1 will receive additional 166Ho-RE within 20 weeks after the 4th and last cycle of PRRT with 7.4 GBq 177Lu-DOTATATE. " 03/01/2021 - "Gallbladder Uptake Mimicking Liver Metastasis on 177Lu-DOTATATE Posttherapy Scan Gallbladder Uptake on 177Lu-DOTATATE Scan." 02/05/2020 - "This multicenter, within-patient RCT will investigate whether IA administration of 177Lu-DOTATATE results in a higher activity concentration in liver metastases compared to IV administration. "
5.	Primitive Neuroectodermal Tumors (PNET) 01/01/2022 - "177Lu-DOTATATE is effective and safe for advanced/metastatic pNETs, which can delay the progression of the disease, may improve patients' survival, and has low treatment-related toxicity and high safety. " 01/01/2022 - "A total of 5 studies, 174 patients, on 177Lu-DOTATATE for advanced/metastatic pNETs were included. " 01/01/2022 - "Search PubMed, Medline, EMBASE and CNKI, VIP, Wanfang databases, from establishment to June 2022, on the study of 177Lu-DOTATATE for advanced/metastatic pNETs, the primary endpoint was to evaluate the treatment effect through DRRs and DCRs. " 01/01/2019 - "Treatment with 177Lu-DOTATATE is a safe and effective therapy resulting in radiological, symptomatic and biochemical response in a high percentage of patients with metastatic functioning pNETs. " 01/01/2022 - "To perform a meta-analysis of the efficacy and safety about 177Lu-DOTATATE therapy for advanced/metastatic pNETs based on the current clinical evidence. "

Related Drugs and Biologics

1.	Radioisotopes (Radionuclides)
2.	Peptide Receptors (Peptide Receptor)
3.	Somatostatin Receptors (Somatostatin Receptor)
4.	Somatostatin (Somatotropin Release-Inhibiting Factor)
5.	Octreotide (Sandostatin)
6.	Everolimus
7.	DOTA-Tyr(3)- 90Y-octreotide
8.	Topotecan (Hycamtin)
9.	Adrenocorticotropic Hormone (ACTH)
10.	nutlin 3

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Salvage Therapy
4.	Contraindications
5.	Intravenous Administration